SFDA approves registration of Pemazyre for cholangiocarcinoma

November 11, 2025

Saudi Gazette reportRIYADH — The Saudi Meals and Drug Authority (SFDA) has authorized the registration of Pemazyre (Pemigatinib) as a monotherapy for adults with regionally superior or metastatic cholangiocarcinoma.

Supply hyperlink

Is Casemiro leaving Manchester United? The Purple Devils linked to former Actual Madrid market goal

Saudi Arabia, Kuwait signal 4 MoUs for bolstering bilateral ties

Popular

SFDA approves registration of Pemazyre for cholangiocarcinoma

Subscribe

SAMA points up to date oversight framework of fee programs and their operators

Saudi air defenses intercept 19 drones over Jap Province on Tuesday

Hailstorm blankets Al-Jouf in white after torrential rains

Belgium, Greece, Netherlands leaders affirm assist for Saudi Arabia in calls with Crown Prince

Emir of Najran honors Saudi lady for saving a household from hearth

More like this
Related

SAMA points up to date oversight framework of fee programs and their operators

Saudi air defenses intercept 19 drones over Jap Province on Tuesday

Hailstorm blankets Al-Jouf in white after torrential rains

Belgium, Greece, Netherlands leaders affirm assist for Saudi Arabia in calls with Crown Prince

About us

The latest

SAMA points up to date oversight framework of fee programs and their operators

Saudi air defenses intercept 19 drones over Jap Province on Tuesday

Hailstorm blankets Al-Jouf in white after torrential rains

Subscribe

SFDA approves registration of Pemazyre for cholangiocarcinoma

Subscribe

More like thisRelated

About us

The latest

Subscribe

More like this
Related